Predict your next investment

Corporation
HEALTHCARE | Drug Development
junshipharma.com

See what CB Insights has to offer

Founded Year

2012

Stage

IPO - III | IPO

About Shanghai Junshi Biosciences

Shanghai Junshi Biosciences (688180.SH) (1877.HK) (NEEQ: 833330) is a biopharmaceutical company dedicated to the discovery and development of drugs and their clinical research and commercialization on a global scale. The company has a pipeline of 13 biologic drug candidates, including immuno-oncology drugs and drugs targeting metabolic and inflammation or autoimmune diseases.

Shanghai Junshi Biosciences Headquarter Location

No.780 Cailun Road, Suite 610 Zhangjiang High-Tec Park, Pudong District

Shanghai, Shanghai, 201203,

China

+86 021-50796193

Latest Shanghai Junshi Biosciences News

Junshi Biosciences starts 2022 with two licensing deals

Jan 11, 2022

Jan. 11, 2022 Barely two weeks into the year, Shanghai Junshi Biosciences Co. Ltd. has already locked down an out-licensing deal and an in-licensing agreement. In a follow-up to their $1.1 billion deal a year ago, Coherus Biosciences Inc. has moved ahead with the right to exercise its option to license Junshi’s JS-006, a recombinant humanized IgG4k monoclonal antibody targeting T cell immunoglobulin and ITIM domain protein (TIGIT). Separately, Junshi has in-licensed antibody “modules,” or Dotbodies, from Dotbio Pte. Ltd. for use in oncology and the development of several multispecific antibodies.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Shanghai Junshi Biosciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Shanghai Junshi Biosciences is included in 1 Expert Collection, including Cancer.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Shanghai Junshi Biosciences Patents

Shanghai Junshi Biosciences has filed 6 patents.

The 3 most popular patent topics include:

  • Monoclonal antibodies
  • Abandoned drugs
  • Biotechnology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/25/2018

10/27/2020

Clusters of differentiation, Immune system, Immunology, Transcription factors, Monoclonal antibodies

Grant

Application Date

7/25/2018

Grant Date

10/27/2020

Title

Related Topics

Clusters of differentiation, Immune system, Immunology, Transcription factors, Monoclonal antibodies

Status

Grant

Shanghai Junshi Biosciences Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Shanghai Junshi Biosciences Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.